系统综述与Meta分析:克罗恩病中氨基水杨酸的使用率、危险因素及费用
该研究检索至2017年4月的安慰剂对照试验,共纳入42项诱导试验和10项维持试验。诱导试验中氨基水杨酸合并处方汇总比例为44%(95%CI:39%-49%),维持试验为49%(95%CI:35%-64%)。多变量Meta回归显示诱导试验中氨基水杨酸使用随时间下降(OR 0.50 [95%CI:0.34-0.74],每10年增量)。
要点
- 诱导试验中氨基水杨酸合并处方汇总比例为44%,维持试验为49%。
- 诱导试验中氨基水杨酸使用随时间下降,每10年OR为0.50。
- 作者认为需要一项确定性试验来指导氨基水杨酸作为克罗恩病维持治疗的常规实践。
核心结论
- 超过三分之一的进入临床试验的克罗恩病患者仍被合并处方氨基水杨酸。
- 作者认为需要一项确定性试验来指导氨基水杨酸作为克罗恩病维持治疗的常规实践。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase和CENTRAL至2017年4月,纳入成人克罗恩病患者接受糖皮质激素、免疫抑制剂或生物制剂治疗的安慰剂对照试验。
- 共纳入42项诱导试验和10项维持试验。
- 采用随机效应模型汇总安慰剂组中合并处方氨基水杨酸的患者比例,并用Meta回归识别相关因素。
- 年度治疗费用采用2016年安大略省药物福利计划估算。
主要发现
- 诱导试验中合并处方氨基水杨酸的汇总比例为44%(95%CI:39%-49%),维持试验为49%(95%CI:35%-64%)。
- 异质性为较高至相当高(诱导试验I2=86.0%,维持试验I2=91.8%)。
- 多变量Meta回归中,诱导试验中氨基水杨酸使用随时间下降(OR 0.50 [95%CI:0.34-0.74],每10年增量)。
- 过去5年的当代试验中仍有35%的克罗恩病患者在使用氨基水杨酸。
关键数值与推荐
- 诱导试验中氨基水杨酸合并处方汇总比例为44%(95%CI:39%-49%)。
- 维持试验中氨基水杨酸合并处方汇总比例为49%(95%CI:35%-64%)。
- 诱导试验异质性I2=86.0%,维持试验异质性I2=91.8%。
- 诱导试验中氨基水杨酸使用随时间下降的OR为0.50(95%CI:0.34-0.74,每10年增量)。
- 过去5年当代试验中克罗恩病患者氨基水杨酸使用比例为35%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 诱导试验异质性I2=86.0%,维持试验异质性I2=91.8%。
- 作者认为需要一项确定性试验来指导氨基水杨酸作为克罗恩病维持治疗的常规实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial. AIMS: To quantify aminosalicylate use in CD clinical trials, identify factors associated with use and estimate direct annual treatment costs of therapy. METHODS: MEDLINE, Embase and CENTRAL were searched to April 2017 for placebo-controlled trials in adults with CD treated with corticosteroids, immunosuppressants or biologics. The proportion of patients co-prescribed aminosalicylates in placebo arms was pooled using a random-effects model. Meta-regression was used to identify factors associated with aminosalicylate use. Annual treatment costs were estimated using the 2016 Ontario Drug Benefit Program. RESULTS: Forty-two induction and 10 maintenance trials were included. The pooled proportion of patients co-prescribed aminosalicylates was 44% [95% CI: 39%-49%] in induction trials and 49% [95% CI: 35%-64%] in maintenance trials. There was substantial to considerable heterogeneity (I2 = 86.0%, 91.8% for induction and maintenance trials, respectively). In multivariable meta-regression, aminosalicylate use has decreased over time in induction trials (OR 0.50 [95% CI: 0.34-0.74] per 10-year increment). While a decline has been seen over time, 35% of CD patients were still using aminosalicylates in contemporary trials from the last 5 years. The estimated annual cost for the lowest price mesalazine (mesalamine) formulation is approximately $32 million for the Canadian CD population. CONCLUSIONS: Over one-third of CD patients entering clinical trials are still co-prescribed aminosalicylates. A definitive trial is needed to inform the conventional practice of using aminosalicylates as CD maintenance therapy.
引用
- Ma C, Dutton SJ, Cipriano LE, et al. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. Aliment Pharmacol Ther. 2018. PMID: 29851091. doi:10.1111/apt.14821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。